Table 3 The Knowledge of PCPs in anticoagulant therapy for NVAF patients
Knowledge of PCPs items | Frequency | Percentage% |
|---|---|---|
How to diagnose AF | ||
ECG | 426 | 85.7 |
Holter | 68 | 13.7 |
Auscultation of the heart and palpation of the pulse | 3 | 0.6 |
Which score tool can be used to predict stroke risk in AF patients | ||
CHADS2 score | 63 | 12.7 |
CHADS2-VASc score | 308 | 62 |
HAS-BLED score | 6 | 1.2 |
ORBIT score | 3 | 0.6 |
Not known | 117 | 23.5 |
Which score tool can be used to predict bleed risk in AF patients | ||
CHADS2 score | 21 | 4.2 |
CHADS2-VASc score | 35 | 7 |
HAS-BLED score | 262 | 52.7 |
ORBIT score | 15 | 3 |
Not known | 164 | 33 |
What risk factors does the CHADS2 score include | ||
Hypertension | 353 | 71 |
Diabetes | 315 | 63.4 |
Dyslipidemia | 132 | 26.6 |
Congestive heart failure | 280 | 56.3 |
Female | 134 | 27 |
Age > 75yo | 334 | 67.2 |
Prior stroke/TIA | 274 | 55.1 |
Not known | 88 | 17.7 |
What risk factors does the CHADS2-VASc score include | ||
Diabetes | 276 | 55.5 |
Prior stroke/TIA/thrombosis | 320 | 64.4 |
Vascular disease | 275 | 55.3 |
Age 65–74 yo | 227 | 45.7 |
Age ≥ 75 yo | 277 | 55.7 |
Hypertension | 296 | 59.6 |
Congestive heart failure/left ventricular dysfunction | 288 | 57.9 |
Female | 208 | 41.9 |
Dyslipidemia | 75 | 15.1 |
Not known | 107 | 21.5 |
What risk factors does the HAS-BLED score include | ||
Female | 68 | 13.7 |
Hypertension | 228 | 45.9 |
Liver dysfunction and renal dysfunction | 228 | 45.9 |
Stroke | 167 | 33.6 |
History of bleeding | 255 | 51.3 |
Unstable INR | 241 | 48.5 |
Alcoholism | 161 | 32.4 |
Concomitant medications (eg. antiplatelet drugs, NSAIDS) | 180 | 36.2 |
Age > 65yo | 200 | 40.2 |
Not known | 182 | 36.6 |
Which indicator should be monitored in AF patients with warfarin | ||
PT | 267 | 53.7 |
APTT | 63 | 12.7 |
INR | 415 | 83.5 |
D-Dimer | 20 | 4 |
Fibrinogen | 13 | 2.6 |
Not known | 12 | 2.4 |
How long should be monitor coagulation function in AF patients with long-term warfarin therapy at a stable period? | ||
Every 2 days | 27 | 5.4 |
Every 7 days | 99 | 19.9 |
Every 30 days | 120 | 24.1 |
Every 3 months | 175 | 35.2 |
Not known | 76 | 15.3 |
What’s the target range of INR in AF patients with warfarin under 75 years old? | ||
1.5–2.4 | 49 | 9.9 |
2.0–3.0 | 213 | 42.9 |
2.0–2.5 | 86 | 17.3 |
1.8–2.6 | 15 | 3 |
2.5–3.5 | 75 | 15.1 |
Not known | 59 | 11.9 |
What’s the target range of INR in AF patients with warfarin over 75 years old | ||
1.5–2.4 | 63 | 12.7 |
2.0–3.0 | 105 | 21.1 |
2.0–2.5 | 138 | 27.8 |
1.8–2.6 | 26 | 5.2 |
2.5–3.5 | 56 | 11.3 |
Not known | 109 | 21.9 |
Which factor is susceptible to the anticoagulation effect of warfarin | ||
The patient’s genes | 213 | 42.9 |
Food | 312 | 62.8 |
Drugs | 420 | 84.5 |
Not known | 49 | 9.9 |
What’s the antagonist that antagonizes warfarin’s anticoagulation | ||
Vitamin K | 455 | 91.5 |
Protamine | 32 | 6.4 |
Prothrombin complex | 93 | 18.7 |
Fresh plasma | 135 | 27.2 |
Not known | 16 | 3.2 |
Which of the following AF patients need to adjust warfarin dose | ||
INR 2.0–3.0 | 32 | 6.4 |
INR 1.0–1.5 | 225 | 45.3 |
INR 3.8–4.5 | 291 | 58.6 |
INR 2.0–2.5 and age ≥ 75y | 125 | 25.2 |
Not known | 119 | 23.9 |
Which medication are the new oral anticoagulants (NOAC)? | ||
Dabigatran | 237 | 47.7 |
Rivaroxaban | 341 | 68.6 |
Apixaban | 316 | 63.6 |
Dicoumarin | 85 | 17.1 |
Edoxaban | 211 | 42.5 |
Not known | 97 | 19.5 |